Trial Data Indicates Targeted, Short Course Radiation Therapy Preserves Urinary Continence and Sexual Function Better Than Surgery in Men With Prostate Cancer

Excerpt from the Press Release:

SUNNYVALE, Calif., Feb. 16, 2023 /PRNewswire/ — Accuray Incorporated (NASDAQ: ARAY) announced today that data from the randomized, multicenter trial PACE-A (PACE – Prostate Advances in Comparative Evidence) indicates that stereotactic body radiation therapy (SBRT), in comparison to surgery, better preserves urinary continence and sexual function in men with localized prostate cancer. The study, which was led by The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, is being presented during an oral session at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) in San Francisco, California.

123 men from 10 UK centers were enrolled in the trial, with 59 ultimately treated with SBRT and 50 with surgery. An analysis of patient reported outcomes found that at two years, significantly fewer patients (4.5%) treated with SBRT reported needing to use urinary pads, which manage urinary incontinence, compared with surgery (47%)¹. Patients treated with SBRT also reported better sexual function after two years than those treated with surgery².

While moderate or serious bowel problems were not reported by many men in the study, those treated with SBRT were more likely (16%) than surgical patients to report minor problems (0%)³.

SBRT is a highly targeted form of external beam radiation therapy that involves the delivery of very high doses of radiation over a small number of treatment sessions, offering convenience for patients.

Click the button below to read the entire Press Release:

Continue Reading The Press Release